-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $225

Benzinga·04/22/2026 12:23:53
Listen to the news
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $220 to $225.